ClinicalTrials.gg
CompletedNCT04135261Updated Apr 18, 2023

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of HBM4003 in Advanced Solid Tumor, sponsored by Harbour BioMed US, Inc.. Completed at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Harbour BioMed US, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a study to evaluate the safety and tolerability of the study drug HBM4003, and to determine the maximum tolerated dose and/or recommended Phase 2 study dose of HBM4003. The study will also look at the anti-tumor activity of HBM4003.The study consists of 2 parts. In Part 1, patients are enrolled into different cohort doses in order to identify the appropriate recommended phase 2 dose (RP2D) or maximum tolerated dose (MTD). In Part 2, participants with metastatic/unresectable melanoma will receive the MTD and/or RP2D established in Part 1 of the study. In Part 1 and Part 2, participants will be administered treatment either once per week or once every 3 weeks.

NOTE: Participants are no longer being recruited to this study.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • advanced solid tumors
03

In context

Lead sponsor

Harbour BioMed US, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form and willingness to comply with study requirements.
  • Part 1 (Dose-escalation): Adult subject ≤ 75 years old with confirmed advanced solid tumors that have progressed after treatment with standard therapies, or for which no effective standard therapy is available, or the subject refuses or has a to standard therapy.
  • Part 2 (Dose-expansion)

    • Adult subjects 18 years and above.

Melanoma Cohort:

  1. confirmed or unresectable melanoma that progressed during or after treatment with a inhibitor (excluding bi-specific antibody) with CTLA-4 blocking function.
  2. Must have received at least one BRAF inhibitor with/without a MEK inhibitor if positive with BRAF V600-activating mutation.

HCC Cohort:

  1. Histologically confirmed metastatic or unresectable hepatocellular carcinoma;
  2. Score of 6 points or less (A5-A6);
  3. Patient with infection will be allowed if he/she is receiving appropriate antiviral therapy for hepatitis B virus (HBV) according to institutional standard of care and HBV DNA level is \< 2000 UI/mL;
  4. Patient with infection will be allowed if he/she is receiving appropriate antiviral therapy for hepatitis C virus (HCV) according to institutional standard of care and HCV antibody returns to negative;
  5. Have received at least one anti-VEGF treatment (either anti-VEGFR TKI or anti-VEGF monoclonal antibody) and/or anti-PD-(L)1 treatment.

RCC Cohort:

  1. Histologically confirmed metastatic or unresectable renal cell cancer (including both clear cell and non-clear histology);
  2. Subjects with clear cell RCC must have failed at least 1 anti-VEGFR TKI treatment and/or anti-PD(L)1 treatment;
  3. For subjects with non-clear cell RCC (e.g. PRCC), treatment naive is permitted.

    • Must have at least one based on (RECIST) 1.1.
    • Willing to undergo tumor unless determined medically unsafe or not feasible.
    • For subjects whose last treatment was immunotherapy, must have disease progression confirmed at least 4 weeks after the initial radiographic evidence of progression;
    • (ECOG) performance status score of 0 or 1.
    • Adequate organ and bone marrow function.
    • Females of may participate provided they agree to practice abstinence; and, if heterosexually active, agree to use at least 2 highly effective methods throughout the study and for 3 months following the last dose of HBM4003; and have a negative serum pregnancy test.
    • Females of non-childbearing potential must be or have been surgically sterilized.
    • Male subjects with a female partner of childbearing potential must agree to practice abstinence or to use a physician-approved contraceptive method throughout the study and for 3 months following the last dose of study drug.
    • of ≥12 weeks.

Exclusion criteria

Exclusion Criteria:

Part 1 and Part 2

  • History of severe or not under well controlled allergic diseases, history of severe drug allergy, or are known to be allergic to macromolecular protein preparations or any component of the study drug.
  • Receipt of anticancer medications or drugs within the following intervals before the first administration of the study drug:

    1. antibody any time prior to study drug administration;
    2. Any PD-1 or PD-L1 or Programmed cell death protein ligand 2 (PDL2)-directed antibody within 8 weeks of study drug administration;
    3. Any cancer vaccines within 3 months prior to first dose of study drug;
    4. within 4 weeks prior to first dose of study drug;
    5. Any other anticancer therapy within 2 weeks prior to first dose of study drug.
  • Not yet recovered from surgery within 28 days prior to first dose of HBM4003 or (immune-related) toxicity related with previous treatment.
  • Concomitant medication or treatments:

    1. Any concurrent chemotherapy, radiotherapy, immunotherapy, or biological therapy for cancer treatment. Concurrent use of hormones on a stable dose for non-cancer related conditions is acceptable. Androgen deprivation therapy (ADT) for advanced prostate cancers is acceptable. Local treatment of isolated non-target lesions for palliative intent is acceptable;
    2. Any traditional anti-tumor herbal medications;
    3. Receipt of red blood cells or infusion, granulocyte colony stimulating factor (G-CSF) or granulocyte monocyte colony stimulating factor (GM-CSF) within 1 week of the first dose of HBM4003.
    4. (>10 mg daily prednisone equivalent) or other medications within 2 weeks of study drug administration; Nasal spray, inhalation, topical corticosteroids or physiological doses of systemic corticosteroids are not included.
  • Have other diseases that may affect the effectiveness and safety of the study drug, such as:

    1. Known or other central nervous system that is either symptomatic or untreated, that requires concurrent treatment;
    2. Active infection requiring treatment with antibiotics within 14 days prior to first dose of HBM4003;
    3. Known history of infection with (HIV) or known acquired immunodeficiency syndrome (AIDS), human T lymphotropic virus 1, virus, or active virus;
    4. Suspected disease, including but not limited to inflammatory bowel disease, autoimmune hepatitis, Guillain-Barre syndrome.
    5. Known primary immunodeficiency;
    6. gastrointestinal disorders (e.g. diarrhea with significant clinical meaning), active gastrointestinal bleeding, or a history of gastrointestinal perforation, acute diverticulitis, intra-abdominal abscess or gastrointestinal obstruction;
    7. Have received allogeneic organ transplantation or hematopoietic stem cell transplantation, or have received autologous hematopoietic stem cell transplantation within 3 months prior to the first dose of study drug.
    8. Subjects with medically confirmed autoimmune coeliac disease are to be excluded. Patients with so-called gluten intolerance or other conditions labelled "coeliac disease" which are not autoimmune in nature and which are well controlled by diet should be medically confirmed as non-autoimmune "coeliac disease" and can be considered for study.
  • Subjects with major cardiovascular disease.
  • History of other uncured malignant diseases, except for non-melanoma skin cancer in situ, superficial bladder cancer, cervical cancer in situ that has been curatively resected, and localized prostate cancer managed by active surveillance.
  • Pregnant or breastfeeding women.
  • Have experienced immune-related GI adverse events on any prior immunotherapy or toxicity that led to permanent discontinuation of prior immunotherapy.
  • Severe cirrhosis, hepatic atrophy, portal hypertension.
  • Main portal vein thrombosis present on imaging.
  • Any prior or current clinically significant ascites (moderate to massive with significantly abnormal liver function).
  • Any history of hepatic encephalopathy within 12 months prior to randomization or require medications to prevent or control encephalopathy.
  • Subjects weighting \< 30 kg.
  • Active or prior documented GI bleeding (e.g. esophageal varices or ulcer bleeding) within 12 months.

Additional criterial for HCC cohort:

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
  • Prior liver transplantation.
  • HBV and HCV co-infection, HBV and HEV co-infection, HBV and HDV co-infection.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Part 1: Dose escalation

    QW - up to 4 (28 day) cycles of treatment (treatment administered 1x weekly) or Q3W - up to 6 (21 day) cycles of treatment (treatment administered 1x q3w) Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee.

    Drug: HBM4003

  • Experimental
    Part 2: Dose expansion

    Treatment administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) established in Part 1, in specific tumor cohorts - Melanoma, HCC and RCC.

    Drug: HBM4003

Interventions

  • Intravenous (IV) administration

06

What researchers measure

Primary outcomes

  1. Part 1: Proportion of subjects with Dose-Limiting Toxicity (DLT)

    Number of subjects who experience DLT events during 28 days (if on QW dosing schedule) or 21 days (if on Q3W dosing schedule)

    Time frame: From Day 1 until disease progression or Day 28, whichever comes first

  2. Part 2: Objective Response Rate (ORR)

    Proportion of subjects with best overall response of complete response (CR) or partial response (PR) per RECIST 1.1

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

Secondary outcomes

  1. Part 1: Objective Response Rate

    Proportion of subjects with best overall response of complete response (CR) or partial response (PR) per RECIST 1.1

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

  2. Part 1: Duration of response

    Time interval from first occurrence of a documented objective response to the time of disease progression, as determined by the Investigator using RECIST 1.1 or death from any cause, whichever comes first.

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

  3. Part 1: Disease control rate

    Proportion of subjects with a best overall response of complete response (CR), partial response (PR) or stable disease (SD).

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

  4. Part 1: Duration of disease control

    Time from data of start of treatment to the date of disease progression or death for subjects who had CR or PR or SD during treatment.

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

  5. Part 1: Tumor shrinkage (The percentage of patients with tumor shrinkage)

    Greatest tumor shrinkage achieved at any follow-up assessment. Measured by radiological (computed tomography \[CT\]/Magnetic Resonance Imaging \[MRI\]) scanning until documented radiographic disease progression according to RECIST 1.1, or loss of clinical benefit after disease progression according to RECIST 1.1

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

  6. Part 1: Cmax (Maximum serum concentration)

    Time frame: Up to 80 days after end of treatment

  7. Part 1: Tmax (Time to reach maximum serum concentration)

    Plasma

    Time frame: Up to 80 days after end of treatment

  8. Part 1: AUC0-inf (Area under the serum concentration versus time curve from time zero to infinity

    Time frame: Up to 80 days after end of treatment

  9. Part 1: Vss (Volume of distribution at steady state)

    Amount of drug in the body divided by plasma concentration

    Time frame: Up to 80 days after end of treatment

  10. Part 1: AUC0-tau (Area under the serum concentration versus time curve from time zero to the dosing interval tau

    Time frame: Up to 80 days after end of treatment

  11. Part 1: t1/2 (Terminal half-life)

    Time frame: Up to 80 days after end of treatment

  12. Part 1: Clearance (CL)

    Time frame: Up to 80 days after end of treatment

  13. Part 1: Cmin (Minimum serum concentration)

    Minimum blood plasma concentration reached by drug prior to administration of second dose

    Time frame: Up to 80 days after end of treatment

  14. Part 1: Rac(Cmax)

    Accumulation ratio calculated from Cmax,ss (maximum (peak) steady state plasma drug concentration during a dosage interval) and Cmax after single dosing

    Time frame: Up to 80 days after end of treatment

  15. Part 1: Rac(AUC0-tau)

    Accumulation ratio calculated from AUCτ,ss and AUC after single dosing

    Time frame: Up to 80 days after end of treatment

  16. Part 2: Disease control rate

    Proportion of subjects with a best overall response of complete response (CR), partial response (PR) or stable disease (SD).

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

  17. Part 2: Duration of objective response

    Time interval from first occurrence of a documented objective response to the time of disease progression, as determined by the Investigator using RECIST 1.1 and iRECIST, or mRECIST for hepatocellular carcinoma (HCC)

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

  18. Part 2: Objective Response Rate

    Proportion of subjects with best overall response of complete response (CR) or partial response (PR) per Response Criteria for Use in Trials Testing Immunotherapeutics (iRECIST), or modified RECIST (mRECIST) for HCC

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

  19. Part 2: Duration of disease control

    Time from data of start of treatment to the date of disease progression or death for subjects who had CR or PR or SD during treatment.

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

  20. Part 2: Tumor shrinkage (The percentage of patients with tumor shrinkage)

    Greatest tumor shrinkage achieved at any follow-up assessment. Measured by radiological (computed tomography \[CT\]/Magnetic Resonance Imaging \[MRI\]) scanning until documented radiographic disease progression according to RECIST 1.1, or loss of clinical benefit after disease progression according to RECIST 1.1

    Time frame: Up to day 206 or until disease progression, unacceptable toxicity, withdrawal of consent, lack of treatment benefit, death or termination of study, whichever comes first.

07

Study locations

17 sites
  • St. George Private Hospital, 1 South Street
    Kogarah, New South Wales 2217, Australia
  • Macquarie University, 2 Technology Place
    Macquarie, New South Wales 2109, Australia
  • Monash Health, Monash Medical Centre, 246 Clayton Road
    Clayton, Victoria 3168, Australia
  • The Alfred Hospital, Commercial Road
    Melbourne, Victoria 3004, Australia
  • Union Hospital affiliated to Tongji Medical College of HUST, Oncology Department, No. 1277 Jiefang Dadao
    Wuhan, Hubei 430022, China
  • Yantai Yuhuangding Hospital, Urology Department, 8th Floor, No. 20 Donglu Road, Zhifu District
    Yantai, Shandong 264000, China
  • The Second People's Hospital of Yibin, Oncology Department, No. 268 South Bank Nanguang Road, Xuzhou District
    Yibin, Sichuan 644000, China
  • Zhejiang Cancer Hospital, Department of Head and Neck Medicine for Rare Diseases, No. 1, Banshan Road, Gongshu District
    Hangzhou, Zhejiang 310011, China
  • Zhenjiang Cancer Hospital, Department of Interventional Therapy, No. 1, Banshan Road, Gongshu District
    Hangzhou, Zhejiang 310011, China
  • Peking University First Hospital, Chemotherapy Department, No. 15 cheniandian Hutong, Annei Street, Dongcheng District
    Beijing, 100034, China
  • Cancer Hospital Chinese Academy of Medical Sciences, Oncology Department, No. 17 Panjiayuan Nanli, Chaoyang District
    Beijing, 199921, China
  • Hunan Cancer Hospital, Intervention Division, 83 Tongzipo Road, Yuelu District
    Changsha, 410006, China
  • Hunan Cancer Hospital, Urology Department, 83 Tongzipo Road, Yuelu District
    Changsha, 410006, China
  • Tianjin Medical University Cancer Institute and Hospital, Biotherapeutic Department, 17 / F, Block C, West Huan-Hu Rd., Ti Yuan Bei, Hexi District
    Tianjin, 300060, China
  • Xuzhou Central Hospital, Oncology Department, No. 199 Jiefang South Road, Quanshan District
    Xuzhou, 221000, China
  • Henan Cancer Hospital, Oncology Department, No. 127 Dongming Road, Jinshui District
    Zhengzhou, 450000, China
  • Queen Mary Hospital, Department of Medicine, 102 Pok Fu Lam Road
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: No — Data generated by this study will be considered confidential by the Investigator, except to the extent that it is included in a publication. The general strategy regarding publication of the study will be mutually agreed upon by the Investigator and Sponsor. The Sponsor reserves the right to manage the publication of all study results. The Investigator agrees that oral and written communication to third parties of any procedures or results from the study is subject to prior written consent of the Sponsor. Presentation material and/or manuscript(s) for publication will be reviewed by the Sponsor prior to submission for publication. Alterations in the material will only be made in agreement between the Investigator and the Sponsor.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Jan 2023, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2019
First posted
Oct 22, 2019
StartActual
Sep 24, 2019
Primary completionActual
Jan 17, 2023
CompletionActual
Feb 15, 2023
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04135261
Lead sponsor
Harbour BioMed US, Inc.
Responsible party
Sponsor
First posted
Oct 22, 2019
Start date
Sep 24, 2019
Primary completion
Jan 17, 2023
Completion
Feb 15, 2023
Last update
Apr 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Porustobart

Start the discussion